Christopher Perkins
Hematology & Oncology · Fresno, CANPI 1396820189
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.7%), consulting fees and education — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Pfizer at 44.3% of the total. Reporting peaked in 2019 at $4,811 and has fallen 99.4% since, to $28 in 2025.
Across 312 payments — averaging $31.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4K
- Daiichi Sankyo Inc.$2K
- AstraZeneca$529
- Puma Biotechnology, Inc.$501
- Merck$410
- GSK$333
- plus $2K from 30 others
Across 79 payments — averaging $1207.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$77K
- Seagen Inc.$15K
- Eli Lilly$2K
- Novartis$775
What the payments were for
- Consulting fees$4,69447%
- Food & beverage$5,13352%
- Education$1041%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 30 | $4,402 |
| Daiichi Sankyo Inc. | 85 | $1,638 |
| AstraZeneca | 27 | $529 |
| Puma Biotechnology, Inc. | 28 | $501 |
| Merck | 23 | $410 |
| GSK | 15 | $333 |
| Amgen | 11 | $255 |
| Seagen Inc. | 12 | $218 |
| Eisai Inc. | 11 | $208 |
| Gilead | 10 | $199 |
| Lilly USA, LLC | 8 | $145 |
| Novartis | 7 | $129 |
| Tersera Therapeutics LLC | 5 | $124 |
| Cardinal Health 108 LLC | 1 | $104 |
| Exelixis Inc. | 5 | $85 |
| Heron Therapeutics, Inc. | 4 | $70 |
| Sanofi | 3 | $65 |
| Clovis Oncology, Inc. | 3 | $54 |
| Genentech USA, Inc. | 3 | $49 |
| Johnson & Johnson(2 entities) | 2 | $47 |
| Mylan Institutional Inc. | 2 | $42 |
| Coherus Oncology, Inc. | 2 | $37 |
| Myriad Genetic Laboratories, Inc. | 2 | $33 |
| Smith+Nephew | 1 | $28 |
| Mayne Pharma Commercial LLC | 1 | $25 |
| Foundation Medicine, Inc. | 1 | $24 |
| Epizyme, Inc. | 1 | $23 |
| Dova Pharmaceuticals | 1 | $23 |
| Cumberland Pharmaceuticals, Inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Bristol Myers Squibb | 1 | $19 |
| Medtronic | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Tesaro, Inc. | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,930 in reported general payments places this provider in the 65th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Fresno
- Haifaa AbdulhaqFresno$347K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.